search
Back to results

Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients (VIVOMIXX)

Primary Purpose

Celiac Disease

Status
Unknown status
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Probiotic Vivomixx
Gluten free diet
Placebo
Sponsored by
University of Milan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Celiac Disease focused on measuring Celiac disease, Gut microbiota

Eligibility Criteria

undefined - 14 Years (Child)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Celiac disease (diagnosis made according to European Society for Paediatric Gastroenterology Hepatology and Nutrition)

Exclusion Criteria:

  • Supplementation with pre/probiotics in the previous 3 months;
  • Antibiotic therapy in the previous 3 months;
  • Comorbidity with other acute (in the previous 3 months) or chronic gastrointestinal disorders
  • Supplementation with group B vitamins for any reason

Sites / Locations

  • Ospedale San PaoloRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Probiotic

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Changes in vitamin B6, folic acid, vitamin B12 and 25'OH vitamin D levels in blood
Changes in homocysteine levels in blood
Changes in ghrelin, chinolinic acid and serotonin levels
Changes in fecal metabolomics (including production of short chain fatty acids verified by gas-chromatography)
Changes in highly sensitive C reactive protein levels
Changes in erythrocite sedimentation rate
Changes in fibrinogen blood levels
Changes in IL-6 blood levels
Changes in Tumor Necrosis Factor alfa blood levels

Secondary Outcome Measures

Changes in body mass index
Changes in systemic arterial systolic and diastolic blood pressure
Changes in height
Changes in weight
Changes in waist circumference
Entity of reduction of triceps skinfold thickness
Changes in prevalence of aphtous stomatitis
Changes in chinolinic acid, serotonin, ghrelin levels in blood
Changes in complete cell blood count
Changes in total cholesterol levels
Changes in HDL cholesterol levels
Changes in LDL cholesterol levels
Changes in triglycerides levels
Changes in Apolipoprotein A1 levels
Changes in Apolipoprotein B levels
Changes in fasting glucose levels
Changes in fasting insulin levels
Changes in auto-antibody anti endomisium titer
Changes in auto-antibody anti-transglutaminase titer
Changes in fecal calprotectin levels
Prevalence of wildtype allele of MTHFR gene by gene sequencing

Full Information

First Posted
November 7, 2019
Last Updated
February 8, 2021
Sponsor
University of Milan
search

1. Study Identification

Unique Protocol Identification Number
NCT04160767
Brief Title
Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients
Acronym
VIVOMIXX
Official Title
Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) on Vitamin B6, B12, 25'OH D, Folic Acid and Omocystein Levels, Metabolic and Inflammatory Status, and Gut Microbiota Metabolomics in a Cohoort of Celiac Patients
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 30, 2019 (Actual)
Primary Completion Date
July 2021 (Anticipated)
Study Completion Date
July 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Milan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Celiac disease is a disorder caused by a disregulation of the immune system which leads to immune response to gluten. Diet therapy is the gold standard of treatment, and the only effective one. Macronutrients and micronutrients deficiency (vitamin D, folic acid, vitamin B12, vitamin B6, iron and zinc), which is in any case far more common in patients who don't follow gluten free diet, can persist in a subset of patients who follow gluten-free diet. Supplementation of vitamins in these patients may have a beneficial role. A recent study in a murine model showed that supplementation with probiotic VIVOMIXX® leads to an increase in expression of vitamin D receptors in proximal and distal colon. This is an interventional controlled randomized double blind study, which evaluates the effect of VIVOMIXX® on vitamin status.
Detailed Description
90 patients with celiac disease who follow gluten free diet will be enrolled. INCLUSION CRITERIA Celiac disease (diagnosis made according to ESPGHAN criteria) EXCLUSION CRITERIA Supplementation with pre/probiotics in the previous 3 months; Antibiotic therapy in the previous 3 months; Comorbidity with other acute (in the previous 3 months) or chronic gastrointestinal disorders Supplementation with group B vitamins for any reason Patients enrolled will be referred to Paediatric Gastroenterology Service in San Paolo Hospital at the time of enrollement (T0) and after intervention therapy (T1, + 4 months). Patients will be randomized in one of the two arms of intervention (VIVOMIXX once a day for 4 months versus placebo once a day for 4 months). VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland. At each time point clinic evaluation, nutritional assessment and blood testing will be made. Data collection will include: Systemic arterial blood pressure; Anthropometric measures (height, weight, body mass index, waist circumference, triceps skinfold) Clinical evaluation including presence/absence of oral aphtous stomatitis Measure of chinolinic acid, serotonin, ghrelin (analysis will be made at Istituto Malattie Infettive, Università La Sapienza, Roma). Dosing of inflammatory markers (analysis will be made at Health Sciences Department, San Paolo Hospital). Metabolomics on stool samples (analysis will be made at Bologna University, Dipartimento di Scienze e Tecnologie Agro-Alimentari, Cesena, with a financial fund by MENDES S.A. - Lugano Switzerland). Routine blood testing including complete blood cell count, vitamin B6, acid folic, vitamin B12, vitamin D 25'OH, fasting glucose, fasting insulin, total cholesterol, LDL and HDL cholesterol, Apolipoprotein A1 and Apolipoprotein B, triglycerides, homocistein, auto-antibody anti endomisium and anti-transglutaminase, Genetic testing for MTHFR gene ESR, highly sensitive CRP, IL6, TNFalfa, fibrinogen Fecal calprotectin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease
Keywords
Celiac disease, Gut microbiota

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Probiotic
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Probiotic Vivomixx
Intervention Description
VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
Intervention Type
Behavioral
Intervention Name(s)
Gluten free diet
Intervention Description
Gluten free diet will be encouraged in both arms
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
Primary Outcome Measure Information:
Title
Changes in vitamin B6, folic acid, vitamin B12 and 25'OH vitamin D levels in blood
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in homocysteine levels in blood
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in ghrelin, chinolinic acid and serotonin levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in fecal metabolomics (including production of short chain fatty acids verified by gas-chromatography)
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in highly sensitive C reactive protein levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in erythrocite sedimentation rate
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in fibrinogen blood levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in IL-6 blood levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in Tumor Necrosis Factor alfa blood levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Secondary Outcome Measure Information:
Title
Changes in body mass index
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in systemic arterial systolic and diastolic blood pressure
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in height
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in weight
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in waist circumference
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Entity of reduction of triceps skinfold thickness
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in prevalence of aphtous stomatitis
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in chinolinic acid, serotonin, ghrelin levels in blood
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in complete cell blood count
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in total cholesterol levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in HDL cholesterol levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in LDL cholesterol levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in triglycerides levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in Apolipoprotein A1 levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in Apolipoprotein B levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in fasting glucose levels
Time Frame
T0 T1 (+4 months)
Title
Changes in fasting insulin levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in auto-antibody anti endomisium titer
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in auto-antibody anti-transglutaminase titer
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Changes in fecal calprotectin levels
Time Frame
Time point 0: day 0 Time point 1: after 4 months
Title
Prevalence of wildtype allele of MTHFR gene by gene sequencing
Time Frame
Time point 0: day 0 (at the enrollement)

10. Eligibility

Sex
Male
Maximum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Celiac disease (diagnosis made according to European Society for Paediatric Gastroenterology Hepatology and Nutrition) Exclusion Criteria: Supplementation with pre/probiotics in the previous 3 months; Antibiotic therapy in the previous 3 months; Comorbidity with other acute (in the previous 3 months) or chronic gastrointestinal disorders Supplementation with group B vitamins for any reason
Facility Information:
Facility Name
Ospedale San Paolo
City
Milan
ZIP/Postal Code
20142
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elvira Verduci, MD PhD Assistant Professor
Phone
+39 0281844508
Email
elvira.verduci@unimi.it

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients

We'll reach out to this number within 24 hrs